Cancer, Malaria & TB Vaccines

Malaria continues to claim an estimated 2 to 3 million lives annually and to account for untold morbidity in the approximately 300 to 500 million people infected annually. Malaria is considered a re-emerging disease, due largely to the spread of drug-resistant parasite strains, decay of health-care infrastructure and difficulties in implementing and maintaining vector control programs in many developing countries. Four species of protozoan parasites cause malaria in humans: Plasmodium falciparum, P. vivax, P. malariae, P. ovale and P. falciparum is responsible for the majority of deaths and most of the severe forms of disease, including cerebral malaria. 2 billion people latently infected with M. tuberculosis 5-10% infected people progress to disease 9 million new TB cases each year 1.5 million TB deaths each year Equivalent to 20 passenger aircraft crashes each day. TB is transmitted by adults with cavitatory disease, HIV infected people carry greater burden of disease. Highest risk of progression from TB infection to active disease, and worst TB morbidity and mortality, compared to older children and adults.

 

    Related Conference of Cancer, Malaria & TB Vaccines

    November 26-27, 2021

    33rd Annual Congress on Immunology and Vaccinations

    Vancouver, Canada
    December 01-02, 2021

    41st Global Summit and Expo on Vaccines & Immunology

    Frankfurt, Germany
    March 09-10, 2022

    6th International Conference on Vaccines and Immunology

    Geneva, Switzerland
    April 18-19, 2022

    Global Summit on Vaccines and Immunology

    Madrid, Spain
    October 07-08, 2022

    34th International Conference on Vaccines and Immunization

    Zurich, Switzerland

    Cancer, Malaria & TB Vaccines Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in